Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Japan Unit Sells iPS Cell Technology Patents To Izumi Of U.S.

This article was originally published in PharmAsia News

Executive Summary

Japan's Bayer Yakuhin says its parent company plans to sell patents it holds on its induced pluripotent stem cells to a U.S. bioventure, iZumi Bio. The technology patents are based on the cell line technology invented by a Japanese researcher, now a researcher at iZumi. The sale by Bayer Yakuhin, a subsidiary of German drug maker Bayer AG, includes both domestic and international patents for the technology. The price was not disclosed. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel